118 results about "Cardiac allograft" patented technology

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The present disclosure provides a meniscal allograft transplantation system and methods of use.

Decellularized and shaped corneal tissue lenticules from allograft and / or xenograft sources and methods of obtaining such lenticules are disclosed. The lenticules are particularly useful as intrastromal lenticular implants in keratoplasty procedures, in which a hinged flap is formed in a patient's cornea and folded back along its hinge to expose the stromal bed of the cornea. The shaped lenticule is then applied to the stromal bed and the flap returned to its original position yielding a new curvature for the cornea and resulting in a desired refractive correction. Fine-tuning of the new refractive power can be achieved by laser ablation either at the same time as implantation or at later time in the event of regression or tonus changes. Methods of decellularizing cornea tissue are disclosed to reduce potential immunogenic reactions on the part of the patient to the implanted lenticule. The lenticules can be further treated to remove immunogenic epitopes. In addition, the posterior and / or anterior surfaces of the lenticule can be treated to assist in intrastromal seating of the lenticule and / or to reduce the likelihood of dislodgement. The methods of forming lenticules can further include preserving at least a portion of the Bowman's membrane. The smoothness of the Bowman's membrane surface also makes it less likely that reopening the flap will dislodge the lenticule.

The present disclosure provides a meniscal allograft transplantation system and methods of use.

Disclosed herein are methods of treating a disease selected from graft-versus-host disease (GVHD), systemic sclerosis (scleroderma), chronic lung allograft dysfunction (CLAD), restrictive allograft syndrome (RAS), and bronchiolitis obliterans syndrome (BOS) using a combination of a BTK inhibitor (such as rilzabrutinib) and belumosudil.

The present disclosure provides a meniscal allograft transplantation system and methods of use.

By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and / or interstitial fibrosis and tubular atrophy CAN / IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and / or subtyping of CAN / IFTA.

A surgical bone cutting system includes a trajectory guide and an osteotome or trepanation tool with a generally square cutting tip that creates a corridor through bone, for example, in the context of spine, through a facet joint or other vertebral structure and to the disc space between two vertebrata for any of a variety of surgical procedures, including but not limited to disc prep and cage insertion. The osteotome fits into the trajectory guide to contact bone and effect creating a bony corridor. In some embodiments, the trajectory guide includes a cylindrical allograft collection chamber, and the trajectory guide and osteotome fit into standard tubular retractors and are agnostic with respect to receiving standard drill bits or a powered auger insertable through a center through channel.

By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with chronic allograft nephropathy and / or interstitial fibrosis and tubular atrophy CAN / IFTA and subtypes thereof. These genes sets are useful for diagnosis, prognosis, monitoring and / or subtyping of CAN / IFTA.

The invention relates to application of a CSPR3 gene in promoting skeletal muscle regeneration. The invention provides a system of a transplantation material for promoting skeletal muscle injury repair and application of the system by utilizing a CSPR3 gene, and reveals that the CSRP3 gene participates in a repair process after skeletal muscle injury. The CSRP3 is knocked down in the skeletal muscle, so that the regeneration capacity of the muscle is destroyed; on the contrary, overexpression of the CSRP3 in the skeletal muscle accelerates the repair process of the skeletal muscle after injury. The skeletal muscle injury repair process can be obviously promoted through an allograft strategy, and the repair time is shortened. The invention provides a direction for promoting the development of a clinical treatment strategy for human skeletal muscle injury.

An acellular dermal matrix (ADM) graft product for a pelvic organ prolapse repair procedure includes an ADM graft derived from full-thickness skin, with a pre-formed shape having one or more of a mesh pattern formed in a central portion thereof, suture punch or slit features or radii transitions about the perimeter. The ADM graft is pre-hydrated, placed in a sterilization package and irradiated to provide a two-year shelf-life for the ADM graft product, which is used in the time-saving, efficient, and effective surgical reconstruction of soft tissue defects. One manufacturing method involves providing a portion of full-thickness donor-derived skin, removing an epidermis, basement membrane, and a fat layer form the portion of the skin, decellularizing the skin to form a portion of ADM graft material, pre-shaping and meshing the ADM graft material, verifying a thickness of the ADM graft material, and packaging the pre-shaped, meshed ADM graft material in a sterilizable package and irradiating for a two-year shelf-life to form the ADM graft product. Other embodiments are also disclosed.

Organ transplantation is currently recognized as the treatment of choice for patients with end-stage renal disease (ESRD). To date, no risk-stratification system exists that adequately predicts transplant patients' individual risk of allograft loss. Described herein the development and validation of an integrative risk prediction score to predict kidney allograft survival of individual patients. A methodology of predicting whether a kidney transplant recipient is at risk of having allograft loss is accomplished by implementing the iBox risk prediction score. The methodology can be achieved using a computer-readable storage medium with program instructions which, when executed by a data-processing unit, cause execution of at least the step of implementing an algorithm of said method of predicting whether a kidney transplant recipient is at risk of having allograft loss.

There is disclosed a defect sizer tool for selection of an appropriately sized pre-cut core for a cryopreserved osteochondral allograft (COCA) transplantation procedure. In an embodiment, the tool includes an elongated connector that provides a handle portion. A ring measurement guide at one end, with a given diameter, and alignable with a cartilage defect to provide an estimated measurement of a diameter. There is disclosed an instrument kit with a pin, a pin guide, and a reamer configured to slidingly receive the pin, blades at one end, and a rotational drive connector at the other end. In an embodiment, a method for a COCA transplantation procedure includes providing an instrument kit, using the pin guide to place the pin in the subchondral bone, and operating the reamer to score surrounding cartilage prior to the reamer bit portion reaming the subchondral bone to the desired depth. Other embodiments are also disclosed.

A device and system for inserting and impacting bone dowel allografts or bone chips into a bone tunnel. The surgical impacting system includes a surgical tamp having a proximal end and a distal end with an elongated shaft extending therebetween. The surgical tamp has an inner channel extending therethrough from the proximal end to the distal end. The distal end of the surgical tamp can have a distal tip. The surgical tamp may have a handle at the proximal end or a proximal tip at the proximal end. The surgical tamp may also have one or more slots extending through the exterior surface of the elongated shaft and into the inner channel. The surgical tamp can be configured for insertion into a delivery tube. The delivery tube serves the purpose of containing a bone dowel or bone chips therein for smooth insertion into the joint.

The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and / or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.

The present disclosure provides compositions, systems, devices, and methods for the delivery of therapeutics. Particularly, the disclosure provides composition, systems, and devices of the delivery of Janus kinase (JAK) inhibitors and uses thereof, such as for inhibiting allograft rejection or treating autoimmune diseases.

The disclosure relates to compositions and methods useful for gene therapy and for the prevention and treatment of cardiac allograft rejection in the transplant setting.

Methods, medical systems, and devices for delivering platelet rich plasma, stem cells, exosomes or other extracellular vesicles, growth factors, neuregulins, hormones, extracellular matrix tissue or microvascular tissue fragments allograft, autograft, or xenograft, anti-inflammatories, steroids, and / or other whole, sectioned, particulated, micronized, or otherwise manipulated substances naturally occurring or synthetic that produce, promote, or enhance angiogenesis, reduce inflammation, reduce oxidative stress, promote healing, and / or otherwise reverse neuropathies or improve function of underlying tissues.

The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

Provided are methods and compositions conditioning a patient for an allogeneic transplantation, wherein the patient's hematopoietic stem cells (HSCs) are depleted with an HSC-depleting composition and the patient is then administered allogeneic cells selected from bone marrow cells, umbilical cord blood cells, hematopoietic stem and progenitor cells (HSPCs), peripheral blood CD34+ cells, and peripheral blood CD34+ and CD90+ cells; optionally the patient is also administered a medicament selected from the group consisting of a T-cell depleting or inhibiting antibody or antibody fragment, NK-cell depleting or inhibiting antibody or antibody fragment, immunosuppressive drug, and any combination thereof. The HSC-depleting composition comprises a compound selected from the group consisting of: an antibody or antibody fragment with specific binding affinity to a protein displayed at the HSC surface, a conjugate comprising an HSC-recognition molecule and a toxin, and any combination thereof.

The present invention relates primarily to JAK1 pathway inhibitors for use in the treatment of chronic lung allograft dysfunction, in particular to JAK1 pathway inhibitors and their use in the treatment of chronic lung allograft dysfunction, such as for example bronchiolitis obliterans syndrome.

Methods for producing allograft tissue by applying an antimicrobial solution to allograft tissue. The antimicrobial solution exhibits antimicrobial activity to make allograft resistant to microbial organisms, such as bacterium. Surface-modified tissue grafts prepared by these methods are also disclosed.

The invention belongs to the field of biomedical engineering, and provides a myocardial organoid hydrogel system containing M2 macrophages as well as a preparation method and application of the myocardial organoid hydrogel system. The preparation method comprises the following steps: polarizing human THP-1 cells to obtain M2 type macrophages; inducing and differentiating the hiPSC into two-dimensional cardiac muscle cells by adopting a micromolecule time sequence regulation mode, and then forming cardiac muscle organoid; the preparation method comprises the following steps: blending M2 type macrophages with an HMAR hydrogel precursor solution, inoculating a myocardial organoid into the precursor solution, performing in-situ crosslinking by ultraviolet irradiation to form a hydrogel system of the myocardial organoid containing the M2 type macrophages, and adding a mixed culture medium for culture. The invention provides a composite system containing three components of the organoid, the M2 type macrophage and the hydrogel with the stress relaxation characteristic, the composite system is applied to transplantation, the allograft success rate of the organoid is increased in an anti-inflammatory, maturation promoting and blood vessel coupling promoting mode, and a possible alternative scheme is provided for organ transplantation.

The invention provides a design method of a bionic meniscus prosthesis on the inner side of a sheep knee joint. Compared with the prior art, the knee joint inner side bionic meniscus prosthesis designed and prepared through the method serves as a synthetic and non-absorbable full meniscus substitute, is implanted into a sheep knee joint in a free and non-fixed mode, and can treat severe meniscus injuries which cannot be repaired through meniscus resection or meniscus suture; and the defects related to the use of a meniscus allograft can be overcome, and the knee joint meniscus prosthesis can completely or partially replace the function of the original meniscus after implantation so as to recover the functional level of the knee joint.

The present disclosure provides a meniscal allograft transplantation system and methods of use.

Methods, medical systems, and devices for delivering platelet rich plasma, stem cells, exosomes or other extracellular vesicles, growth factors, neuregulins, hormones, extracellular matrix tissue or microvascular tissue fragments allograft, autograft, or xenograft, anti-inflammatories, steroids, and / or other whole, sectioned, particulated, micronized, or otherwise manipulated substances naturally occurring or synthetic that produce, promote, or enhance angiogenesis, reduce inflammation, reduce oxidative stress, promote healing, and / or otherwise reverse neuropathies or improve function of underlying tissues.

The present invention relates to the combination of certain benzenesulfonamide thiazole compounds with anti-cancer therapies for use in treating cancer in patients identified as overexpressing GRP78. Using a mouse model of colorectal cancer (CT26 allograft model) and several in vitro cancer cell line models, the inventors have shown that combination therapy using the benzenesulfonamide thiazole compound HA15 and anti-cancer therapies, such as immunotherapeutic agents, chemotherapeutic agents, or targeted therapeutic agents, significantly improved survival and potently suppressed tumor growth compared to monotherapy containing either the benzenesulfonamide thiazole compound or the anti-cancer agent alone.